Episealer® Knee technology and clinical results to be presented at European congress
Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® Knee technology and clinical results are being presented at the 5th International Conference on Meniscus Science and Surgery (Luxembourg, July 7-9, 2022). The presentation is held by Prof Karl Eriksson from Stockholm South Hospital and The Karolinska Institute, Stockholm, Sweden. The presentation will focus on the expected clinical outcome after resurfacing of cartilage defects in the knee, and the latest results from an ongoing European multicentre study will be presented as a part of the presentation.
“The segment which we are focusing on, patients in the gap age who are too old for biological treatment alternatives and too young for knee replacements, has become an established topic for discussion on the scientific meetings. The delegates at this meeting, having a focus on knee joint preservation, is a highly important group of surgeons and we are proud that our technology will be presented as a part of the scientific program”, says Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: